3-氟-4-羟基-5-甲基苯甲腈 | 1033955-92-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-氟-4-羟基-5-甲基苯甲腈
• 英文名称: 3-fluoro-4-hydroxy-5-methylbenzonitrile
• CAS: 1033955-92-8
• 化学式: C₈H₆FNO
• 分子量: 151.14
• InChiKey: CSJPWYQDPZHGKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-溴-2,4-二氯嘧啶 、 3-氟-4-羟基-5-甲基苯甲腈 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(5-Bromo-2-chloropyrimidin-4-yl)oxy-3-fluoro-5-methylbenzonitrile
  参考文献：
  名称：

  Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses

  摘要：

  Further investigation of the recently reported piperidine-4-yl-aminopyrimidine class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out. Thus, preparation of a series of N-phenyl piperidine analogs resulted in the identification of 3-carboxamides as a particularly active series. Analogs such as 28 and 40 are very potent versus wild-type HIV-1 and a broad range of NNRTI-resistant mutant viruses. Synthesis, structure-activity relationship (SAR), clearance data, and crystallographic evidence for the binding motif are discussed. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.068
• 作为产物：
  描述：

  4-bromo-2-fluoro-6-methylphenol 、 氰化亚铜 以 二甲基亚砜 为溶剂， 以80%的产率得到3-氟-4-羟基-5-甲基苯甲腈
  参考文献：
  名称：

  Non-nucleoside reverse transcriptase inhibitors

  摘要：

  本发明提供了用于治疗HIV感染、预防HIV感染、治疗AIDS或ARC的化合物。本发明的化合物具有如下式I所示的结构，其中R1、R2、R3、R4、R5a、R5b、R6a、R6b和X的定义如本文所述。本发明还公开了使用上述定义的化合物治疗HIV感染的方法，以及含有这些化合物的药物组合物。

  公开号：

  US20080146595A1

文献信息

• SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES
  申请人：Snow Alan

  公开号：US20110104055A1

  公开（公告）日：2011-05-05

  Compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of amyloid and synuclein.

  本发明提供了化合物及其药学上可接受的盐、它们的合成和标记、含有它们的制药组合物以及它们在治疗淀粉样疾病中的应用，包括Aβ淀粉样蛋白病，如阿尔茨海默病中观察到的病变、IAPP淀粉样蛋白病，如2型糖尿病中观察到的病变，以及突触核病，如帕金森病中观察到的病变，并制造用于此类治疗的药物。此外，本发明还提供了所述化合物作为成像剂的应用以及用于体内淀粉样蛋白和突触核成像和检测的方法。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2921480B1

  公开（公告）日：2017-10-11
• US9777005B2
  申请人：——

  公开号：US9777005B2

  公开（公告）日：2017-10-03
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Kestesz Denis John

  公开号：US20080146595A1

  公开（公告）日：2008-06-19

  The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

  本发明提供了用于治疗HIV感染、预防HIV感染、治疗AIDS或ARC的化合物。本发明的化合物具有如下式I所示的结构，其中R1、R2、R3、R4、R5a、R5b、R6a、R6b和X的定义如本文所述。本发明还公开了使用上述定义的化合物治疗HIV感染的方法，以及含有这些化合物的药物组合物。
• Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses
  作者：Guozhi Tang、Denis J. Kertesz、Minmin Yang、Xianfeng Lin、Zhanguo Wang、Wentao Li、Zongxing Qiu、Junli Chen、Jianghua Mei、Li Chen、Taraneh Mirzadegan、Seth F. Harris、Armando G. Villaseñor、Jennifer Fretland、William L. Fitch、Julie Qi Hang、Gabrielle Heilek、Klaus Klumpp

  DOI：10.1016/j.bmcl.2010.08.068

  日期：2010.10

  Further investigation of the recently reported piperidine-4-yl-aminopyrimidine class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out. Thus, preparation of a series of N-phenyl piperidine analogs resulted in the identification of 3-carboxamides as a particularly active series. Analogs such as 28 and 40 are very potent versus wild-type HIV-1 and a broad range of NNRTI-resistant mutant viruses. Synthesis, structure-activity relationship (SAR), clearance data, and crystallographic evidence for the binding motif are discussed. (c) 2010 Elsevier Ltd. All rights reserved.